Abstract
The tetracycline-controlled Tet-Off and Tet-On gene expression systems are used to regulate the activity of genes in eukaryotic cells in diverse settings, varying from basic biological research to biotechnology and gene therapy applications. These systems are based on regulatory elements that control the activity of the tetracycline-resistance operon in bacteria. The Tet-Off system allows silencing of gene expression by administration of tetracycline (Tc) or tetracycline-derivatives like doxycycline (dox), whereas the Tet-On system allows activation of gene expression by dox. Since the initial design and construction of the original Tet-system, these bacterium-derived systems have been significantly improved for their function in eukaryotic cells. We here review how a dox-controlled HIV-1 variant was designed and used to greatly improve the activity and dox-sensitivity of the rtTA transcriptional activator component of the Tet-On system. These optimized rtTA variants require less dox for activation, which will reduce side effects and allow gene control in tissues where a relatively low dox level can be reached, such as the brain.
Keywords: Tet-On system, Tet-Off system, Transcription regulation, Doxycycline, Gene expression, rtTA, tTA, TetR.
Current Gene Therapy
Title:Tet-On Systems For Doxycycline-inducible Gene Expression
Volume: 16 Issue: 3
Author(s): Atze T. Das, Liliane Tenenbaum and Ben Berkhout
Affiliation:
Keywords: Tet-On system, Tet-Off system, Transcription regulation, Doxycycline, Gene expression, rtTA, tTA, TetR.
Abstract: The tetracycline-controlled Tet-Off and Tet-On gene expression systems are used to regulate the activity of genes in eukaryotic cells in diverse settings, varying from basic biological research to biotechnology and gene therapy applications. These systems are based on regulatory elements that control the activity of the tetracycline-resistance operon in bacteria. The Tet-Off system allows silencing of gene expression by administration of tetracycline (Tc) or tetracycline-derivatives like doxycycline (dox), whereas the Tet-On system allows activation of gene expression by dox. Since the initial design and construction of the original Tet-system, these bacterium-derived systems have been significantly improved for their function in eukaryotic cells. We here review how a dox-controlled HIV-1 variant was designed and used to greatly improve the activity and dox-sensitivity of the rtTA transcriptional activator component of the Tet-On system. These optimized rtTA variants require less dox for activation, which will reduce side effects and allow gene control in tissues where a relatively low dox level can be reached, such as the brain.
Export Options
About this article
Cite this article as:
Das T. Atze, Tenenbaum Liliane and Berkhout Ben, Tet-On Systems For Doxycycline-inducible Gene Expression, Current Gene Therapy 2016; 16 (3) . https://dx.doi.org/10.2174/1566523216666160524144041
DOI https://dx.doi.org/10.2174/1566523216666160524144041 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Micro-Nanomaterials for Tumor Microwave Hyperthermia: Design, Preparation, and Application
Current Drug Delivery Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Translocator Protein as a Promising Target for Novel Anxiolytics
Current Topics in Medicinal Chemistry Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3
CNS & Neurological Disorders - Drug Targets The Plasma Membrane: A Target and Hurdle for the Development of Anti- A? Drugs?
Current Drug Targets - CNS & Neurological Disorders Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology Neuroprotective Strategies for the Treatment of Inherited Photoreceptor Degeneration
Current Molecular Medicine Editorial (Thematic Issue: Focal Adhesion Kinase and Cross-Linked Signaling In Cancer)
Anti-Cancer Agents in Medicinal Chemistry Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
Current Cancer Drug Targets Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design